Kornimate/medical-research-clean huggingface dataset:
enhanced primary care and technology for children with chronic disease

Conditions: Overweight; Obesity; Asthma

Summary: using technology alongside a pediatric chronic disease specialist and behavior specialist, the investigators are planning to help care for and coordinate the healthcare of children with chronic diseases, particularly childhood obesity, diabetes and asthma in miami's most vulnerable communities. the university of (um) miller school of medicine (msom) pediatrics and telehealth departments propose to leverage information and communications technologies (ict) in an innovative approach to improve the quality, access and efficiency of pediatric services for children and their families.

participants will be recruited from an outpatient clinic site with diagnoses of overweight, obesity or asthma. there will be a total of 6 visits during the study at approximately 1 month intervals. during the first and last visits, pre- and post-intervention assessment points, quality of life, adherence to medical regimen, physical activity and dietary habits will be gathered. during the follow-up visits, only quality of life will be surveyed. at the initial visit, for overweight children, the patients will be assessed for their behaviors and attitudes regarding eating, physical activity, sedentary time and motivation. if the patient has asthma, the pediatrician will assess understanding of the disease. throughout the course of the study the chronic condition pediatrician and behavior specialist will see patients in a consult capacity for their chronic condition, but the patient will continue to see their regular pediatrician for primary care needs. at every visit the pediatrician will review changes since the last visit, and then provide education directed at overweight/obesity and/or asthma. the behavior health specialists will then work with the patients to develop a plan on how to follow their treatment plan and achieve healthy behaviors. all of the participants will receive access to technology in the form of a tablet computer for the duration of the study. the tablets will be installed with software to help educate patients and their families about asthma and overweight/obesity and track progress in managing them. in addition, all follow-up visits except for the final one will be done using the tablets and a video-conferencing app. for the first and last visits, all patients will be seen in-person in the clinic. all of the follow-up visits will be done via a video-conferencing app on the tablet computers.

Eligibility criteria:
inclusion criteria: * patients who receive care at the borinquen clinic * aged five through 18, inclusive * diagnosis of asthma (requiring medication) or overweight (greater than or equal to 85% for age). * fluent in english or spanish. * parents/guardians must be fluent in english or spanish. exclusion criteria: * none.

Keywords: chronic condition telehealth nutrition exercise
radiofrequency ablation in the pain management of knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the aim of this study is to assess the safety and efficacy of radio frequency thermo-coagulation on the genicular nerve (rftgn) and intra-articular pulsed radio frequency (iaprf) for knee osteoarthritis (koa) to improve physical activity , range of joint movement , pain intensity and quality of life.

after obtaining the consent from patients and being informed about the study and potential risks , all patients were randomly assigned to the rftgn, iaprf, and intraarticular steroid injection (ias) groups. all procedures were performed under the guidance of c-arm x-ray machine. the observation indicators of this study were the numeric rating scale (nrs), oxford knee scale (oks), and perceived global effect (gpe). the time points for the assessment were 1-week, 1-month, 3-months, 6-months and 9-months after the treatment.

Eligibility criteria:
* inclusion criteria: 1. patients diagnosed with koa based on the american college of rheumatology criteria 2. age 18-70 years 3. grade 2 or 3 koa based on the kellgren-lawrence classification 4. patients who did not respond to conservative treatment (physiotherapy, oral nsaids, and/or intraarticular injections of hyaluronic acid and corticosteroid) for 3 months 5. duration of knee pain ≥ 3 months 6. numeric rating scale (nrs) ≥ 5 points within 24 h prior to admission. * exclusion criteria: 1. grade 1 or 4 koa based on the kellgren-lawrence classification 2. severe liver, kidney, cardiovascular, and respiratory disease 3. abnormal blood coagulation 4. skin infections in the puncture region 5. patients who previously underwent knee arthroscopy, tka, rftgn, or iaprf 6. mental disorders or inability to complete the follow-up observational form 7. patients with bilateral knee pain.
nephrocare mhealth project: telemonitoring of blood pressure

Conditions: Chronic Kidney Diseases; Blood Pressure

Summary: the nephrocare mhealth project supports patients with chronic kidney disease with a mobile application and telemonitoring. the application includes the follow-up of blood pressure.

patients that are included in the nephrocare mhealth project send their blood pressure results through an app or online website. the clinical decision support system will alert the patient, as well as the general practitioner and the hospital when the blood pressure is too high or low. in addition the clinical decision support will calculate monthly averages and all the data are connected with the electronic patient files.

Eligibility criteria:
inclusion criteria: * dutch-speaking * signed and approved informed consent * follow-up by nephrology at the university hospitals leuven or general hospital groeninge exclusion criteria: * no dutch-speaking * impaired cognitive condition or medically unstable
pilot study of vestibular rehabilitation training for panic disorder with vestibular dysfunction

Conditions: Vestibular Diseases; Agoraphobia; Panic Disorder

Summary: objectives: i. evaluate whether vestibular rehabilitation training is of value in reducing anxiety symptoms in patients with panic disorder with or without agoraphobia who have vestibular dysfunction as identified by clinical vestibular tests.

protocol outline: during the first 4 weeks of study, patients meet with a clinical nurse specialist once a week for approximately 1 hour. during this time, the nature of the anxiety disorder is explained and exposure to previously feared situations is encouraged. only patients who remain symptomatic at a stable level following self-exposure will proceed with rehabilitation training. patients meet with a physical therapist once a week for 4 weeks to further evaluate the extent of problems associated with balance. then, patients undergo weekly 1 hour exercises for 8 weeks with the physical therapist, focusing on sensation, head and eye coordination, movement with eyes opened and closed, and gait. concurrently, patients meet with the clinical nurse specialist every 4 weeks during and after physical therapy to evaluate the effects of vestibular treatment on anxiety symptoms. training is continued if patient is symptomatic; otherwise, patient is discharged from study.

Eligibility criteria:
* diagnosed panic disorder with or without agoraphobia * vestibular dysfunction, as defined by abnormalities in the caloric and/or rotational tests * continued symptomatology after general instructions of the importance of exposure to feared situations * absence of acute symptoms of anxiety or depression assessed to need immediate clinical care

Keywords: agoraphobia anxiety disorder disease-related problem/condition neurologic and psychiatric disorders panic disorder rare disease vestibular diseases
pico breast reduction clinical study looking at incision healing complications

Conditions: Delayed Healing

Summary: the purpose of this study is to see if the use of a single-use negative pressure wound therapy system (npwt) will have an effect on the reduction of post-surgical incision healing complications following breast reduction surgery and to assess the medium-term aesthetic appearance and quality of the resultant scar, compared with standard of care dressings.

the aim of the present study is to assess the efficacy and cost-effectiveness of the single-use negative pressure wound therapy (npwt) system (pico) with regard to the reduction of postsurgical incision healing complications during the immediate postoperative treatment phase, and to assess the medium-term aesthetic appearance and quality of the resultant scar, in patients undergoing reduction mammoplasty, compared to standard care.

Eligibility criteria:
inclusion criteria: * female patient's ≥ 18 years old * the patient is able to understand the trial and is willing to consent to the trial * patient has undergone an elective surgical procedure for bilateral reduction mammoplasty * patients postsurgical incisions are of similar length exclusion criteria: * pregnant or lactating females * patients on steroids or other immune modulators known to impact healing which may affect scar appearance * patients with tattoos in the area of the incisions * patients with skin conditions (cutis laxa etc.) that would result in poor healing or widened scars * patients with a known significant history of scar problems i.e. hypertrophic scaring or keloids * patients who in the opinion of the investigator may not complete the study for any reason * patients with a known history of poor compliance with medical treatment * patients who have participated in this trial previously and who were withdrawn * patients with known allergies to product components (silicone adhesives and polyurethane films (direct contact with wound), acrylic adhesives (direct contact with skin), polyethylene fabrics and super-absorbent powders (polyacrylates) (within the dressing) * incisions that are actively bleeding * exposure of blood vessels, organs, bone or tendon at the base of the reference wound * incisions \> 12 inches (30cm) max linear dimension

Keywords: surgical incision reduction mammoplasty healing complications negative pressure wound therapy
prg combined with autologous bmmscs for treatment of diabetic foot ulcer

Conditions: Diabetic Foot Ulcer

Summary: to investigate the treatment effect between traditional treatment and transplantation of autologous prg combined with autologous bmmscs for treatment of diabetic foot ulcer.

60 diabetic foot ulcer in our hospital will divide into 3 groups: group a (20 diabetic foot ulcer who give traditional treatment), group b (20 diabetic foot ulcer who give traditional treatment and transplantation of autologous platelet rich gel)，group c (20 diabetic foot ulcer who give traditional treatment and transplantation of autologous platelet rich gel combined with autologous bone marrow mesenchymal stem cells). the age, height, weight, blood glucose, glycosylated hemoglobin a1c（hba1c）, lipid, blood pressure, course of disease, wound healing rate,transcutaneous oxygen pressure,amputation rate,hospital stay will record respectively. and high-sensitive c-reactive protein (hscrp) and tumor necrosis factor-α（tnf-α） will detect as baseline. after each group's treatment, change from baseline of all indexes will record, one way analysis of variance will be analyzed the significantion among 3 groups.

Eligibility criteria:
inclusion criteria: * diabetic foot according to the wagner is 2-3 graded; exclusion criteria: * type 1 diabetes mellitus,presence of autoimmune diabetes; * gestational diabetes; * patients with heart, liver, or renal function impairment;presence of severe infections or cerebrovascular disease.

Keywords: platelet rich gel bmmscs diabetic foot ulcer
young adults with life threatening cow's milk allergy: risks of decrease bone mineralization and methods of calcium supplementation

Conditions: Bone Mineral Density in Cow's Milk Allergic Patients

Summary: diet is the only source for calcium and the most important dietary source are dairy products. this presents a difficulty for children with ige-mediated cow's milk allergy, who are unable to consume milk. we noted that ige-cma allergic young adults have a significant decrease in bone mineral density (bmd) compared to international reference values and also to geographically and age matched normal controls. working hypothesis: young adults with ige-cma have significantly lower bmd than age and gender matched controls. this can be reversed by introducing dairy products following recovery from allergy, or by enriching the diet via other calcium sources.

the aims of the study are 1. to study the prevalence and severity of reduced bmd among ige-cma allergy patients 2. to estimate the potential of recovery from reduced bmd after administration of milk during oral immunotherapy. 3. to determine the efficacy of intervention with other (non-dairy) calcium enriched diets in ige-cma young adults, utilizing several methods to direct compliance. methods: we will study the bone mineral content (bmc), bmd, serum values of bone turnover factor, dietary and lifestyle questionnaires of 150 post pubertal ige-cma patients with no history of dairy consumption and 150 age and gender matched normal controls. separately, we will compare the above values of these patients to those of former ige-cma patients who now ingest milk after recovery from allergy. finally, we will examine the effects of including non-dairy dietary sources of calcium in ige-cma patients, with different groups receiving different degrees of interventional guidance. the study will provide insight into the bone health of cma patients, and provide guidance as to effective dietary treatments and its implementation. furthermore, important nutritional data on the best methods for intervention to reduce osteoporosis will likely be learnt, that should have far reaching ramifications, not only to this particular population, but to osteoporosis patients, at large.

Eligibility criteria:
inclusion criteria: all post pubertal males and females diagnosed with ige-mediated cmp allergy were eligible puberty in both sexes was determined by signs of tanner stage iv. females were at least two years after menarche the minimal age for girls was 16 years and for boys 17.5 years old. the maximal age to be included in this study was 30 years old exclusion criteria: female's history of pregnancy, and in both genders any 128 bone affecting disease/treatment, systemic steroid treatment for a period longer than 4 weeks or multiple short courses of systemic steroid treatments.
effects of wbv in children with hemiparetic cp

Conditions: Cerebral Palsy; Whole Body Vibration; Spastic Hemiplegia; Motor Performance

Summary: the aim of this study was to investigate short and long-term effects of whole body vibration therapy on spasticity and motor performance in children with hemiparetic cerebral palsy in addition to conventional physiotherapy. twenty-six patients undergoing conventional physiotherapy in a private rehabilitation center were included in the study. patients were randomized to treatment and control groups. study was completed with a total of 22 cases (11 for each group). at the beginning of the study, cases were evaluated with gross motor function measure-88, legsys spatio-temporal gait analyzer, sportkat550tm portable computerized kinesthetic balance device and modified ashworth scale. cases in the treatment group were treated with compex-winplate for 8 weeks, 3 times a week, 15 minutes a day in one session. all cases were reevaluated immediately after the treatment and 12 weeks after the treatment.


Eligibility criteria:
inclusion criteria: * patients with hemiparetic cp * patients were followed-up and treated by a special rehabilitation center * aged between 6-18 years * patients could walk independently without using assistive devices exclusion criteria: * any other neurological diseases * cooperation problems * visual or auditory disability

Keywords: cerebral palsy spasticity motor performance whole-body vibration conventional physical therapy
biodistribution and dosimetry evaluation of [124i]fiau

Conditions: Prosthesis Related Infections

Summary: this protocol will evaluate the biodistribution and dosimetry of \[124i\]fiau in both healthy volunteers and patients with prosthetic joint infections. this pilot study will also investigate the safety and tolerability of \[124i\]fiau.


Eligibility criteria:
the following are the main inclusion criteria for all subjects: 1. males or females age \> 18 years 2. informed consent 3. subjects with chronic medical conditions such as hypertension and diabetes should be considered stable by the principal investigator 4. women should be postmenopausal or surgically sterile 5. able to return for all study assessments in addition, the following main inclusion criteria apply for subjects with suspected prosthetic joint infection: 1. operative intervention planned in the 30 days following study enrollment 2. prosthetic joint implant in site for more than 3 months prior to enrollment the following are the main exclusion criteria for all subjects: 1. unable to comply with study requirements 2. indication in the opinion of the principal investigator for surgery within 48 hours of presentation. 3. receipt of any antibiotic therapy in the 2 weeks preceding imaging 4. immunosuppression, e.g., human immunodeficiency virus (hiv) infection, s/p organ transplantation, receipt of steroids for \> 10 days at \> 10 mg of prednisone equivalent daily within the 90 days prior to enrollment 5. requirement for any medication that predisposes to lactic acidosis (e.g., metformin, iron, isoniazid and salicylates; see appendix a) 6. requirement for any medication that has potential mitochondrial toxicity, e.g., nucleoside analogues (zidovudine, didanosine, stavudine) 7. history of an inherited mitochondrial disorder (e.g., leber's hereditary neuropathy, neuropathy, ataxia, retinitis pigmentosa and ptosis \[narp\], myoneurogenic gastrointestinal encephalopathy \[mngie\], myoclonic epilepsy with ragged red fibers \[merff\] and mitochondrial myopathy, encephalomyopathy, lactic acidosis and stroke-like syndrome \[melas\] 8. chronic hepatitis b virus (hbv) or hepatitis c virus (hcv) infection 9. pre-existing myopathy or neuropathy 10. abnormal liver function tests defined as alanine aminotransferase (alt) \> the upper limit of normal (uln), aspartate aminotransferase (ast) \> uln, gamma glutamyl transferase (ggt) \> uln 11. alcohol use \> 3 units per day in men or 2 units per day in women or active intravenous drug use 12. creatinine clearance \< 30 ml/min 13. body mass index \> 40 14. life expectancy \< 6 months 15. hypersensitivity to iodine

Keywords: phase i fiau fialuridine biodistribution dosimetry prosthetic joint infection pet-ct
glucagon enhanced insulin absorption in diabetes mellitus type 1

Conditions: Type 1 Diabetes

Summary: the investigators will study the effect of microdoses of glucagon at the site of subcutaneous insulin injection. the investigators have unpublished data from anesthetized pigs indicating a major enhancement of insulin absorption.

people with type 1 diabetes will come fasting in the morning to the research facility on two separate days. both days participants will have a breakfast of their own choice and their regular dose of meal insulin injected. lyumjev will be used. frequently collected blood sampled will be analysed for glucose, insulin and glucagon for 3.5 hours. the procedures will be exactly the same both days except that on one of the days they will be randomised to a small dose of glucagon that will be injected at exactly the same site as lyumjev insulin is injected.

Eligibility criteria:
inclusion criteria: 1: type 1 diabetes for at least 1 year. 2. age 18 - 70 years. 3. last known hba1c \<86 mmol/mol. 4. treated with continuous subcutaneous insulin infusion (csii) by an insulin pump or multiple daily insulin injections (mdii). exclusion criteria: 1. pregnant women or women trying to conceive. 2. any chronic disease, including psychiatric illness, judged incompatible with participation in the study. 3. unfit for participation for any reason judged by the investigators. 4. known hypersensitivity to glucagon or any of the excipients of the drug formulation. 5. known phaeochromocytoma. -
ngenla subcutaneous injection special investigation

Conditions: Growth Hormone Deficiency Without Epiphyseal Closure

Summary: the purpose of this study is to learn about the long-term safety and effects of ngenla. ngenla is approved for treatment of ghd (growth hormone deficiency) without epiphyseal closure under daily medical practice. registration criteria of this study are the patients who: * have ghd without epiphyseal closure and receiving ngenla for the first time. * are boys less than 15 years or girls less than 13 years of age at the start of treatment with ngenla. all patients in this study will receive ngenla according to the prescriptions. we will examine their experiences for a long time. this will help us to determine the safety and effects of ngelna for long-term use. patients will be followed up from the date of first ngenla treatment until november 30, 2027.

this is a multi-center cohort study in patients with ghd without epiphyseal closure receiving ngenla® subcutaneous injection. the investigators complete the case report form (crf) based on the information extracted from the medical record created in daily medical practice.

Eligibility criteria:
patients who satisfy all of the registration criteria are subject to this study. registration criteria 1. patients with ghd without epiphyseal closure who receive this drug for the first time after the date of contract for this study. 2. boys who are less than 15 years and girls who are less than 13 years of chronological age at the start of treatment with this drug.

Keywords: growth hormone deficiency (ghd) recombinant human growth hormone (hgh) once-weekly injection somatrogon
paradoxical lucidity in severe end-stage dementia

Conditions: Dementia

Summary: cognitive decline in dementia is considered irreversible, however episodes of paradoxical lucidity (pl) in severe dementia suggest other mechanisms may be in play. beyond anecdotal reports of transient pl events occurring in patients predominantly in late-stage dementia and typically lasting anywhere from a few minutes to several hours, little is known about pl. the study team proposes to develop and conduct a mixed methods prospective study of pl during end stage advanced dementia, creating a definition and measurement scale for pl in advanced dementia, and identifying the potential electro cortical biomarkers of pl in advanced dementia. this study will be divided in two phases: phase i and phase ii. during phase i, the study team will collect sufficient and necessary data through an online survey and focus groups as well as assess the safety and feasibility of using symptom diaries (also known as daily trackers or journals) and real-time video eeg monitoring (veeg). after preliminary review of the study procedures, the pi will decide whether to move onto the phase ii. the second phase will aim to expand the study population and refine study methods as well as create a definition and measurement scale for pl in advances dementia.


Eligibility criteria:
inclusion criteria: * age \> 18 years * advanced (severe) dementia diagnosed using the global deterioration scale (gds) with a score of 7 or the palliative performance scale (pps) with a score of less than 30% * accepted for hospice care based on the medicare eligibility guidelines * no longer being provided with nutrition or fluids * anuria (dry diaper) or less than 200cc urine (almost dry diaper) in any 24-hour period exclusion criteria: * cognitive or functional impairment due to a diagnosis other than dementia * dementia with a gds score \<7 (mild, moderate, moderately severe dementia). please refer to rationale outlined for inclusion criteria 2.